
Clinuvel Pharmaceuticals Limited: updates and filings
Price
$4.66
November 20, 2026Market cap $235M
What Ploutos Investor adds for Clinuvel Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from FY2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Oct 30, 2026Annual report (foreign company)for the period to Jun 30, 2026Form20-F
- Oct 30, 2026Current report (foreign company)Form6-K
- Oct 15, 2026Current report (foreign company)Form6-K
- Oct 7, 2026Current report (foreign company)Form6-K
- Oct 2, 2026Current report (foreign company)Form6-K
- Oct 1, 2026Current report (foreign company)Form6-K
- Sep 9, 2026Current report (foreign company)Form6-K
- Aug 27, 2026Current report (foreign company)Form6-K
- Aug 20, 2026Current report (foreign company)Form6-K
- Aug 12, 2026Current report (foreign company)Form6-K
- Jul 30, 2026Current report (foreign company)Form6-K
- Jul 28, 2026Current report (foreign company)Form6-K
- Jul 27, 2026Current report (foreign company)Form6-K
- Jul 23, 2026Current report (foreign company)Form6-K
- Jul 22, 2026Current report (foreign company)Form6-K
- Jul 22, 2026Current report (foreign company)Form6-K
- Jul 17, 2026FilingFormSEC STAFF ACTION
- Jul 17, 2026Exchange certification of a listingFormCERT
- Jul 15, 2026Correspondence with the SECFormCORRESP
- Jul 9, 2026Correspondence with the SECFormCORRESP
- Jul 6, 2026Correspondence with the SECFormCORRESP
- Jun 15, 2026Correspondence with the SECFormCORRESP
- Jun 15, 2026FilingForm20FR12B
- Apr 23, 2026Letter from the SECFormUPLOAD
- Apr 17, 2026FilingFormDRSLTR
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Oct 30, 2026 | 20-F | Annual report (foreign company)for the period to Jun 30, 2026 | Document |
| Oct 30, 2026 | 6-K | Current report (foreign company) | Document |
| Oct 15, 2026 | 6-K | Current report (foreign company) | Document |
| Oct 7, 2026 | 6-K | Current report (foreign company) | Document |
| Oct 2, 2026 | 6-K | Current report (foreign company) | Document |
| Oct 1, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 9, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 27, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 20, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 12, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 30, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 28, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 27, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 23, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 22, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 22, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 17, 2026 | SEC STAFF ACTION | Filing | Document |
| Jul 17, 2026 | CERT | Exchange certification of a listing | Document |
| Jul 15, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jul 9, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jul 6, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jun 15, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jun 15, 2026 | 20FR12B | Filing | Document |
| Apr 23, 2026 | UPLOAD | Letter from the SEC | Document |
| Apr 17, 2026 | DRSLTR | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 7, 2004.
The full analysis
What do Clinuvel Pharmaceuticals's filings show?
The filings are where every one of Clinuvel Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.